Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
The move strengthens Sanofi’s presence in adult immunization by combining Dynavax’s innovative vaccines with Sanofi’s global scale and development capabilities
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
The move is expected to be crucial during health crises
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Subscribe To Our Newsletter & Stay Updated
